Literature DB >> 10867716

Blunted erythropoietin response to anemia in patients with Type 1 diabetes.

P Cotroneo1, B Maria Ricerca, L Todaro, D Pitocco, A Manto, V Ruotolo, S Storti, P Damiani, S Caputo, G Ghirlanda.   

Abstract

BACKGROUND: It is known that patients with renal failure have normochromic normocytic anemia due to impaired endogenous erythropoietin (EPO) synthesis. The aim of this work was to determine whether low serum erythropoietin (s-EPO) levels play a role in the pathogenesis of anemia in patients with Type 1 diabetes without overt nephropathy.
METHODS: We included in the study 13 patients with Type 1 diabetes whose Hb levels were <11 g/dl. Blood cell count, s-EPO, urinary albumin excretion rate (AER), HbA(1c), glomerular filtration rate, serum iron, serum ferritin, the presence of neuropathy, retinopathy and nephropathy were determined.
RESULTS: Ten out of 13 patients with anemia (77%) had a blunted EPO response to anemia. All ten patients with low EPO levels had autonomic neuropathy; five had clinical nephropathy but with serum creatinine<1.6 mg/dl. Three patients were treated with rHuEPO and showed an improvement in their anemia after treatment.
CONCLUSION: The majority of patients with Type 1 diabetes who had anemia also had low EPO levels. The pathogenesis of this phenomenon is probably multifactorial. Autonomic neuropathy appears to play a role, but it is not sufficient, per se, to be the only cause. Dysautonomia might enhance the effect of renal damage. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867716     DOI: 10.1002/1520-7560(200005/06)16:3<172::aid-dmrr117>3.0.co;2-d

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  9 in total

Review 1.  Anemia and diabetic nephropathy.

Authors:  Eberhard Ritz
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

2.  Ethnic differences in anemia among patients with diabetes mellitus: the Diabetes Study of Northern California (DISTANCE).

Authors:  Ameena T Ahmed; Alan S Go; E Margaret Warton; Melissa M Parker; Andrew J Karter
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

3.  Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.

Authors:  Robert E Schmidt; Dongyan Feng; Qiuling Wang; Karen G Green; Lisa L Snipes; Michael Yamin; Michael Brines
Journal:  Exp Neurol       Date:  2011-08-18       Impact factor: 5.330

Review 4.  Erythropoietic stress and anemia in diabetes mellitus.

Authors:  Dhruv K Singh; Peter Winocour; Ken Farrington
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

5.  Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.

Authors:  Robert E Schmidt; Karen G Green; Dongyan Feng; Denise A Dorsey; Curtis A Parvin; Jin-Moo Lee; Qinlgi Xiao; Michael Brines
Journal:  Exp Neurol       Date:  2007-10-29       Impact factor: 5.330

6.  Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy.

Authors:  Sofija Davidović; Nikola Babić; Sandra Jovanović; Sava Barišić; Desanka Grković; Aleksandar Miljković
Journal:  BMC Ophthalmol       Date:  2019-11-14       Impact factor: 2.209

7.  Erythropoetin receptor expression in the human diabetic retina.

Authors:  Shaival S Shah; Stephen H Tsang; Vinit B Mahajan
Journal:  BMC Res Notes       Date:  2009-11-25

8.  Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates.

Authors:  Niels Grote Beverborg; Niek Verweij; Ijsbrand T Klip; Haye H van der Wal; Adriaan A Voors; Dirk J van Veldhuisen; Ron T Gansevoort; Stephan J L Bakker; Pim van der Harst; Peter van der Meer
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

9.  Markers of Anemia in Children with Type 1 Diabetes.

Authors:  Ewa Rusak; Anna Rotarska-Mizera; Piotr Adamczyk; Bogdan Mazur; Joanna Polanska; Agata Chobot
Journal:  J Diabetes Res       Date:  2018-05-31       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.